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Abstract 
 
Anesthesia care is delivered world wide on a daily basis.  Provision of anesthesia cares for 
surgical, obstetrical, or pain management procedures mandate a thorough understanding of 
physiology, pathophysiology, and pharmacology.  Nearly 4 million anesthetics are delivered in 
the United States each year and the impact of genetics on anesthesia care is becoming greater.  
Anesthesia providers make prescriptive decisions based on an individual patient’s disease 
processes, proposed surgical or therapeutic procedure, and a thorough clinical history.  The age 
of personalized medicine is upon us and the ability to use genetic testing to help predict how a 
patient will respond to various medications is here.  By using genetically coded single nucleotide 
polymorphism programming of the metabolic pathways in the liver, drugs responsiveness can be 
more precisely predicted and explained.  This dissertation focuses on the clinical utility of 
genetic testing to predict drug responsiveness (pharmacogenomics) among anesthesia providers 
with a focus on treating acute pain.  Specifically, the following research question is addressed:  
What is the clinical utility of pharmacogenomic testing to support prescriptive decision making 
among anesthesia providers.  To answer this research question, a mixed-method sequential 
qualitative quantitative study was carried out.  The conclusions of this research are (a) anesthesia 
providers lack knowledge concerning pharmacogenomic testing, (b) anesthesia providers are 
concerned about potential ethical and economic issues surrounding genetic testing, and (c) 
anesthesia providers perceive a potential benefit to using pharmacogenomic testing as it relates 
to making prescriptive decisions.  Further work is necessary to more carefully refine the 
instrument used to measure clinical utility as well as future intervention work aimed at increasing 
anesthesia provider knowledge about pharmacogenomic testing. 
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Chapter 1: Introduction 
Knowledge in the Field of Study 
 Pharmacogenomic testing is becoming more widely used to help make 
personalized healthcare decisions, however, a stark gap exists in the literature about the 
perceived clinical utility of pharmacogenomic testing in supporting prescriptive decision-
making in anesthesia practice.  The majority of anesthetic pharmacogenomic testing lies 
focuses on the cytochrome P450 (CYP450) enzyme system that metabolize medications.1  
CYP450 enzymes are found primarily in the liver and their activity level is in some part 
responsible for how a patient will respond to a medication.2-4  Although there is 
heterogeneity among patients current estimations purport 60 CYP450 pathways; 
replicated studies have shown six of these are responsible for 90% of all metabolism of 
all available medications.1 
 Each individual possesses a different CYP450 system that results in varied 
responses to medication between people.1 Pharmacogenomic testing can help categorize 
how an individual’s variation in genetic penetrance and expressivity will control for 
CYP450-mediated drug metabolism rates.5  Traditionally, prescriptive decisions for 
medications are made mostly on a trial-and-error basis.  These methods use sound science 
by combining what is individually known about a patient’s physiology and 
pathophysiology so they are somewhat patient specific.1 Unfortunately, this approach to 
making prescriptive decisions is not completely objective or accurate and the incidence of 
adverse drug events, unnecessary risk exposure, and elevating costs mandate the need to 
use better methods to inform clinical prescriptive decisions. 
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Current Practice 
In the area of pain management, the administration of opioid analgesics to help 
control acute pain in the perioperative period is the mainstay of practice.  It is well 
established that opioid analgesics carry significant risk even when administered at 
normally accepted doses.6,7 The risks associated with opioid analgesics include 
respiratory depression, respiratory arrest, and even death.  Additionally, the side effect 
profile of opioid analgesics is profound and can include pruritis, nausea, vomiting, 
constipation, urinary retention, and somnolence and can impact patient satisfaction and 
adherence to prescribed therapy.5,8 Better and more patient-specific best practice methods 
are warranted as needed as they can help to avoid these possible severe events and 
diminish the more minor risks. 
 The ability to personalize care with pharmacogenomics is based on an 
individual’s genetic profile (genotype) and the penetrance and expressivity of many 
different single nucleotide polymorphisms (SNP) that influence the way the liver 
metabolizes drugs through the CYP450 systems.2 The specific concern for opioid 
analgesics is the CYP2D6/2C9 SNP that help control metabolism in a slow, fast, and 
ultra-fast manner.2,3 Because the CYP2D6/2C9 SNP control for the metabolism of 
opioids, testing and interpretation of these genotypes can help the anesthesia provider 
better plan and dose opioids to achieve optimal analgesic effects without the burdensome 
and dangerous side effects typically seen with inappropriate opioid selection and dosing.6 
This will help to ensure the right drug is prescribed at the right dose in the right patient at 
the right time.  By avoiding excessive doses of potentially lethal opioid analgesics in 
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patients with genotype-specific programmed slow opioid metabolism, adverse drug 
events can be avoided.6 
  
Figure 1.  Four potential outcomes of medication administration 
Pharmacogenomic Testing  
 There are many commercially available, low cost pharmacogenomic tests 
available to practitioners to help inform prescriptive decision-making regarding 
medications.1 These tests include in-office testing for very specific SNPs or larger assays 
that will help practitioners determine patient response to a large variety of medications.  
Outcome studies demonstrate superior patient responses and decreased side effect 
profiles when pharmacogenomic testing is used by practitioners to help understand 
clinical prescriptive decisions; however, uptake by the healthcare community remains 
extremely low.2,6,7,9-14 The perceived clinical utility of pharmacogenomic testing, 
specifically among anesthesia providers, is unknown.  A gap exists in the literature 
pervades regarding how anesthesia providers perceive clinical utility of 
pharmacogenomic testing.  
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Clinical Utility 
 For a test, treatment, or technology to be considered useful it must be 
demonstrated that it has clinical utility.15 To date, data exists of the perceived clinical 
utility of pharmacogenomic testing among healthcare providers as a whole and among 
family practice physicians, however, no studies exist demonstrating clinical utility of 
pharmacogenomic testing among anesthesia providers.15,16 5,13,14,17-19 The feasibility of 
conducting clinical utility perception studies has been well-established, however, there 
are no data to demonstrate the knowledge, education, perceived benefits and barriers, and 
perception of pharmacogenomic testing use to inform prescriptive decision-making 
among anesthesia providers in the United States. 
Pharmacogenomic Testing in Anesthesia 
 The purpose of manuscript one was to exploration of the concept of genetic 
predisposition as it related to healthcare decision-making.20 An exhaustive literature 
review to explore the concept of genetic predisposition with the understanding that the 
concept of genetic predisposition is the underpinning science behind pharmacogenomic 
testing was conducted.  It was discovered that the concept of genetic predisposition is 
immature overall but does have some degree of pragmatic maturity.20 Based on this 
analysis, the concept of genetic predisposition can be defined as the use of genetic testing 
to predict disease, stratify risk, identify susceptibility and guide prevention of disease.20 
 The purpose of manuscript two was to complete an integrative review of the 
instruments currently used to measure acute pain.  In order to measure a concept, in this 
case a physiologic concept of pain, an instrument with sound psychometrics is necessary.  
In order for an anesthesia provider to understand the effectiveness of an intervention 
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aimed at treating (or reducing) pain levels, appropriate instruments with sound 
psychometric measurements are necessary.  In this review, it was determined that most 
clinically-used instruments to measure acute pain are not psychometrically solid, 
however, there are five instruments currently available that have moderate psychometric 
properties rendering them clinically useful for acute pain measurement.21 
 Despite an understanding of the concept of genetic predisposition and known 
psychometrically-sound instruments that can be used to measure acute pain, no data 
exists on the perceived clinical utility of pharmacogenomic testing among anesthesia 
providers.  There are also no instruments that measure clinical utility of 
pharmacogenomic testing among anesthesia providers.  The purpose of manuscript three 
of this dissertation, therefore, is to report on the results of a mixed-method study that 
aimed at describing the perceived clinical utility of pharmacogenomic testing among 
currently practicing anesthesia providers.  Additionally, this manuscript reports on the 
fundamental psychometric testing of a yet-to-be developed future instrument aimed at 
measuring the degree of clinical utility of pharmacogenomic testing among anesthesia 
providers. 
Theoretical Framework 
 The framework guiding this dissertation was the Centers for Disease Control and 
Prevention’s (CDC) ACCE Model of Public Genomics.22  In this model, the CDC has 
proposed a conceptual model for comprehensive evaluation of clinical utility of various 
types of genetic testing.  The model’s dimensions include analytic validity, clinical 
validity, clinical utility, and ethical, legal, and social implication of a genetic test.  The 
specific portion of the model used in this dissertation is the outer ring of clinical utility. 
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Figure 2.  ACCE Model of Public Genomics 
 Collectively, the three manuscripts of this dissertation describe the clinical utility 
of a genetic test.  The specific genetic test is pharmacogenomic testing as it relates to 
helping anesthesia providers make decisions about opioid analgesics to treat acute pain.  
Guided by the CDC ACCE Model of Public Genomics, this body of work seeks to 
answer the research question:  What is the perceived clinical utility of pharmacogenomic 
testing among anesthesia providers? 
  
	  
	   7	  
 
Chapter 2: Genetic disposition:  A principle-based concept analysis 
Riddle, D.  (2014).  Published in the International Public Health Journal, 6(1) 23-32.20 
Abstract 
 
Aim.  To report an analysis of the concept of genetic predisposition. 
Background.  The discipline of genetics has evolved tremendously in the past few 
decades.  The impact of genetics on nursing practice and research is burgeoning and the 
concept of genetic predisposition is emerging in the literature. 
Design.  Concept analysis 
Data sources.  A total of seventeen articles in the English language are used. 
Method.  The principle-based concept analysis method was used to analyze the concept 
of genetic predisposition. 
Results.  Genetic predisposition has overall conceptual immaturity.  The epistemological, 
linguistic, and logical principles all show mild to moderate maturity as related to genetic 
predisposition.  The concept has pragmatic maturity with the caveat that the contextual 
placement of the concept be understood. 
Conclusion.  A definition of the concept of genetic predisposition is suggested as well as 
a direction for future research. 
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Genetic Predisposition:  A Principle-Based Concept Analysis 
Within the profession of nursing, the incorporation of genetics into caring for 
patients has become almost commonplace in the past several years.  The use of genetics 
includes diagnostics, screening, and helps inform clinical treatment decisions.23  Within 
the emerging field of genetics, there lie several concepts that are frequently encountered 
such as genetic relevance, genomics, pharmacogenomics, and genetic testing.  The goal 
of this paper is to add clarity to the concept of genetic predisposition through a formal 
concept analysis using the Principle Based Concept Analysis method.  This method is 
chosen because it helps explain the current state of the science related to a concept and is 
useful when the concept is relatively immature.24 
Concept Definition 
Genetic predisposition is the combination of the terms ‘genetics’ and 
‘predisposition’, each of which could be individually considered concepts but the 
combination of the two words leads to a third unique concept.  Using many sources, this 
section aims to first define genetics and predisposition independently.  After the 
independent definitions are examined, the concept of genetic predisposition as a whole 
will be explored. 
Genetics, as defined by the Oxford English Dictionary (OED),25 is the “scientific 
study of inherited variation in living organisms, and the cellular and molecular processes 
responsible for this.”  Furthermore, the OED specifies that the branch of biology 
concerned with studying inherited variation be called genetics.  Historically, the term 
genetics first appeared in 1905 when scientists were trying to describe the study of 
heredity and the term genetics was agreed upon as the best definition.   The scientific 
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community agreed that the term gene would be used to describe the basic unit of heredity 
with genetics being the study of heredity.  In 1968, the New England Journal of Medicine 
first published a scientific paper about the genetics of alpha1-antritypsin deficiency and 
used the term genetics to describe the cause of this protein deficiency.25 
Predisposition is a term defined as the pre-existing tendency to suffer from a 
disease of medical condition.26  Its use dates back to 1622 when Henry VII was described 
as having the “sweating sickness” as a result of the predisposition of the seasons.  Later 
in 1707, physicians began using the term predisposition to describe a patient’s likelihood 
of contracting a disease based on their family history of a similar disease.   In this 
century, the term predisposition has been used to describe someone who is pre-
symptomatic for a disease but has not yet demonstrated clinical signs for the particular 
disease.26  An example of this is a person who has a family history of diabetes but has yet 
to have elevated blood glucose levels.27 
In order to define genetic predisposition, the combination of genetics and 
predisposition must be used.  For the purposes of this submission, combining these words 
gives genetic predisposition the following meaning:  a preexisting tendency to suffer a 
disease or medical condition based upon inherited variations of living organisms.  Stated 
another way, genetic predisposition is the likelihood of having a disease or medical 
condition as determined by specific cellular or molecular markers that have been 
inherited. 
Other Definitions 
The concept of genetic predisposition is widely used in scientific literature 
regarding the study of genetics.  In the arena of primary genetic research, scientists use 
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the term genetic predisposition to describe the molecular and cellular markers of 
disease.28  In this context, genetic predisposition has no human element but rather the 
results of a genetic testing profile that is paired with a disease process.  Thus, there is no 
particular relationship between a test result and a patient; it is simply an example of 
statistics indicating result X will mean disease Y has a high probability of occurring.28  In 
this realm, genetic predisposition could be considered a cold, isolated concept. 
Elsewhere, when the term genetic predisposition is used, scientists are referring to 
a particular patient or set of patients.  There are known genetic tests that will yield results 
related to specific diseases.  The concept of genetic predisposition, in this case, is used to 
describe those patients at risk for developing the disease in question.29  In this light, 
genetic predisposition is a proposition of what might happen or what could happen based 
on genetic profiling.30  One example of a disease is epilepsy and the various genetic tests 
for the disease.  Emerging as a central focus of epilepsy research, genetic testing has 
identified more than 20 genes thought responsible for epilepsy.29  Patients possessing one 
or more of these particular genes are considered to have a genetic predisposition for 
development of epilepsy. 
Another use of the concept of genetic predisposition is not found in the biological 
science literature but rather in social science and theological literature.  In this venue, 
genetic predisposition is seen through the lens of vulnerability and the unknown.31  In 
this light, the concept of genetic predisposition is highly correlated with risk; that is to 
say genetic predisposition is inherently paired with a risk for disease and comorbidity.31  
Using genetic testing to determine the risk of developing cancer highlights an example of 
this use of genetic predisposition.  There are many in the population that would not like 
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to know this information and by receiving such testing for genetic markers of cancer 
significant psychological harm may occur.31 
A final use of genetic predisposition is centered on the idea of susceptibility or 
vulnerability.  In this context, genetic predisposition refers to the anticipated response to 
a drug or treatment.28  An example of this would be the use of genetic testing to 
determine a patients genetic predisposition to the effects of opioid pain medication.9  In 
this context, genetic predisposition can help predict adverse or unwanted side effects of 
medications.  Testing can be performed to help inform clinical decision making to ensure 
the best possible patient outcome. 
Conceptual Framework 
Genetic predisposition can be grounded in the Systems Biology Conceptual 
Framework.  Systems biology poses that science is derived from interdisciplinary study 
of complex systems and then synthesized to investigate cellular-level biological 
processes.32  This approach is holistic and involves specific applications to the study of 
genes, their proteins for which they code, and the resulting phenotype.  Specific to 
genetics research, the Systems Biology Framework allows for a strategy to study diseases 
with a genetic basis.  Interdisciplinary teams of nurses, physicians, epidemiologists, and 
biostatisticians can work together using one conceptual framework.32 
In the Systems Biology Framework, the nurse scientist assumes that one 
intervention can result in a dynamic process in multiple levels of the person such as the 
genetic, molecular, cellular, and organ system level.32  In application to genetics, it is 
Systems Biology Theory that says genetics could have an impact on disease initiation or 
progression.  An important aspect of Systems Biology Theory allows for the impact of 
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environment and intervention to impact the resulting disease.32  Studies undertaken using 
Systems Biology Theory help to understand the complex interaction of genes and their 
impact on disease progression and treatment.  A conceptual model of Systems Biology 
Theory is listed below, Figure 1. 
Figure 1.  Systems Biology Conceptual Model 
 
Literature Review 
Structure of Search 
A purposeful and exhaustive literature search is obligatory to increase rigor and 
decrease bias in a concept analysis.33  A three-step search strategy was utilized in this 
concept analysis.  An initial limited search of MEDLINE and CINAHL was undertaken 
followed by analysis of the text words contained in the title and abstract, and of the index 
terms used to describe the article.  This search was performed to identify historical views 
of genetic predisposition.  A second search using all identified keywords and index terms 
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were undertaken across all included databases.  Thirdly, the reference list of all identified 
reports and articles was searched for additional studies. 
Databases included in the exhaustive search included EBSCOhost (CINAHL, 
MedLine, eBook Collection, and MasterFILE Premier), PubMed, Science Direct, and Pro 
Quest.  Libraries from two universities were utilized as well as the assistance of a 
reference librarian to help define search terms and Boolean phrases appropriate to the 
concept.  The search was limited to articles in English language only as translation 
services are not available.  Additionally, only articles discussing human subjects were 
included.  There are numerous studies that speak to genetic predisposition in animal and 
plant species as well.  The timeframe for the search was 1950 through October 2012.  All 
articles were retrieved either electronically or through interlibrary loan services. 
Search Results 
The initial search was in the EBSCOhost database that includes CINAHL, 
MedLine, eBook Collection and MasterFILE Premier search engines.  Keywords used 
included genetic predisposition, genetic AND predisposition, gene* predisposition, and 
“genetic predisposition” in all data fields.  The searches were limited to English language 
and human subjects only.  This search strategy resulted in a total of 722 articles. 
The next search was in the ProQuest database.  Keywords used were genetic 
predisposition, “genetic predisposition”, and genetic AND predisposition.  Again, the 
language was limited to English and human subjects were only examined.  This search 
strategy results in 233 articles for consideration. 
The final literature search was using Science Direct.  The keywords included 
genetic predisposition, “genetic predisposition”, and gene* predisposition.  Limiting this 
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search to English language only, a total of 110 articles were returned.  After looking 
closely at these articles, 20 were excluded in this initial search based on non-human 
subjects.  Therefore, Science Direct yielded 90 articles for the purposes of this concept 
analysis. 
 A total of 1822 articles were retrieved using the outlined search strategy.  An 
initial review of the title allowed for exclusion of 1451 articles.  The abstracts of the 
remaining 371 articles were then read and considered.  Studies includes in this analysis 
must have distinctly discussed genetic predisposition and defined some aspect of the 
meaning of this term.  Many studies retrieved that mentioned genetic predisposition but 
after careful analysis these studies did not speak comprehensively about this term.  
Additional articles were excluded from analysis because they were editorial statements.  
Included in the literature matrix are primary research studies and review articles speaking 
directly to the concept of genetic predisposition.  This process resulted in 17 articles for 
analysis.  The details for each article are presented in Table 1, below. 
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-genetics can help 
predict liver injury 
(often highly 
predictable) but  not 
guarantee results 
-review article 
looking at 12 primary 
research articles 
-no detailed search 
strategy noted 



































between high and 
low penetrance 
genetic mutations 
 31 -prediction of 
disease (focus on 
cancer) 
-prevention of 
disease based on 
results of testing 
-genetic testing can 
be seen like 
mammogram and 
pap smear – testing 
for disease that’s 
preventable if 
treated 
-to test a model of 
intentions based on 
theory of reasoned 
action 
-n=1824 adults, 




(intent to get genetic 
testing) 
-What is the influence 
of religion on 
decisions to undergo 
genetic testing? 
-4 hypotheses tested 
-religion affiliation 
results in negative 
feelings towards 
genetic testing 
-if question was 
phrased as “disease 
is completely 
treatable and GT 
can predispose you 





looking at religion, 
previous experiences, 
and question wording 
on attitudes about 
genetic testing 
-not all hypotheses 
were completely 
clear or addressed in 
discussion/conclusion 
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-seen as a positive 
predictive factor 
 
-pilot study, n=109 
-all morbidly obese 
patients 









-Is there a gene 
implied in opioid 
pharmacodynamics in 
obese patients? 
-3 SNPs were found 
among the group 
-A118G was seen in 




-presence of this 
SNP may be 




-pilot study so results 
are not generalizable 
to entire population 
or even all obese 
patients 
-very clear that 
further testing on this 
gene in obese 




 36 -forecasting of 
disease 
-filtering of genetic 
information to 
determine highest 
prediction rate of 
disease 
-identification of 





from the Familial 
Breast Cancer Study 
-prospective, cohort 
study 
-Explore feasibility of 
using gene exome 
sequencing technique 
to predict breast 
cancer rates 
-exome sequencing 












-utility of this 
technique is not fully 
known 
-spoke extensively of 
prediction power of 










	   17	  







 37 -prediction of 
suicide is related to 
genetic markers 
-ability to help 
determine who is 









and mood disorders 
and suicide 
-not enough 





of varying studies 
-controlling for 
extraneous variables 
in inclusion criteria 
gave strength to 
conclusions 










-Is there an 
association between 
SNPs and breast 
cancer – based on age 
and parity? 
-6 distinct SNPs do 
put patients at 
higher risk of 
development of 
breast cancer 
-no association with 
age or parity 
-huge sample size 
-all women in 
Sweden born 
between 1923-1950 
invited to participate 
-results only 
applicable to women 
of northern European 
origin? 
 39 -incidence of 
disease 
-determining the 





-What is the current 





based on a 
particular set of 
high risk, medium 
risk, and low risk 
genetic markers 
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 29 -risk associated 









-review article -What is the current 








molecular basis of 
disease 




-results are a basis 
for determining risk 
estimation 
-great review of the 










-genetic testing can 
show risk of 
potential negative 
outcomes 








-What is the current 
state of the science 
regarding genes and 
cardiac disease? 
-23 of 33 previously 
thought of genetic 
loci do not increase 
risk of CAD 
-CAD is propagated 
by factors other 
than pure genetics 
-lifestyle and 
environment play 




variants are not 
ready for routine 
testing 
-interesting insight 
into the need to back 
down from genetic 
testing until the 
science is more solid 
-good explanation 
about what was know 
and why that is now 
being dismissed 
-discussed risk as 
very negative and 
decreasing risk as 
very positive 
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 16 -genetic testing 





risk is still present 
-genetics and 
environment 




-n=40 in depth 
interviews 
-from previous 
sample of epilepsy 
study group at 
Columbia University 
-How do people with 
epilepsy and their 
family members 
understand genetics? 
-How do people with 
epilepsy and their 
family members 
perceive risks and 
benefits of genetic 
testing? 
-What do people’s 
hope and fears 
regarding genetic 
testing reveal about 
the local moral 








genetics is seen as 
risk stratification 














which was seen as an 
unexpected finding 
 31 -genetic makeup 
can predict risk of 
disease 
-genetic makeup 
can be protective in 
some cases 












-Pilot study to 
determine an 
association between 





SNPs (AA variant) 
and development of 
depression 
-seen as a risk (if 








-pilot study, limited 
results 
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-risk is based on 
the genetic makeup 
-nested, cohort study 
-n=5,499 
-examined specific 
lipid loci in study 
and control patients 
-examined more than 
specific SNPs, tested 
for gene-wide loci 




to dyslipidemia and 
DM-2 development 
-significant increase 
in risk of 
developing DM-2 





based on poor 
mapping of some 
genes coding for 
lipids 
-large sample size 
-well constructed 
treatment and control 
groups 
-question the 





Susceptibility 33 -certain genes 
render a patient 
susceptible to a 
disease 
-patterns of 
expression lead to 
higher rates of 
disease 
-metaanalysis of 12 
primary studies 
-calculated OR and 
CI for all studies 
-overall found a high 
and low frequency 
gene related to lung 
cancer 
-Metaanalysis of 12 
primary studies 
-Is there a single gene 
that show patient 
susceptibility to lung 
cancer? 
 
-no single gene is 








-well done statistical 
analysis 
-calculated CI for 
each study to add 
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statistics looking at 
MS and genetic 
makeup 
-convenience sample 
of patients at 3 
clinics with known 
MS 
 
-Aim was to 
investigate 
association to 
multiple sclerosis all 
three classes of HLA 
I genes 
-2 of the 3 HLA 
classes predispose 
patient to MS 
-1 HLA gene 
presence offers 
protection from 








 35 -susceptibility is 
the strongest term 
that can be applied 










-To discuss the 
association between 










IDDM and other 
diseases in genetic 
markers 
-good overview of 
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 36 -genetic 
predisposition to 








lifestyle play a 






-genotyped for 12 
SNPs known to 
increase BMI 
 
-Can the genetic 
predisposition to 
obesity be modified 
by physical activity 
-those people with 
genetic markers for 
obesity can reduce 
incidence of obesity 
by 40% with 
physical activity 
-lifestyle 
modification can be 





-limited to the 
European population, 
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Analysis of Concept 
 The question to be addressed in this analysis is:  “What is the current state of the 
science regarding the concept of genetic predisposition”?  A principle-based concept 
analysis method is employed to perform this analysis.  The basis of the principle-based 
concept analysis is evaluation of the concept in four key areas:  epistemological, 
pragmatic, linguistic, and logical.24  It is through these four principles that the concept 
can be evaluated and the state of the science surrounding genetic predisposition as a 
concept can be established.  For the purposes of this analysis, the four undergirding 
principles will be addressed individually and attention will be given to defining the 
concept of genetic predisposition as a statement of the state of the science.   
Epistemological 
 The epistemological principle refers to the nature of knowledge.24  When 
examining the epistemological principle, a determination of the concept’s clarity and 
differentiation from other concepts is analyzed.  Genetic predisposition is not clearly 
defined nor well differentiated from other concepts.  Lack of clear definition is partly due 
to the relatively immature nature of genetic predisposition.12 Literature can be grouped 
into three overarching themes associated with the definition of genetic predisposition:  
predictive, risk and susceptibility to disease.  These three terms have different meanings 
that are often based on the context in which they are discussed. 
 In order for a concept to be considered mature, it must be clearly positioned in the 
body of literature.24  The concept of genetic predisposition is not well situated in the 
literature and is not well-differentiated form other descriptions of risk or prediction.  Lack 
of the clear definition of genetic predisposition is based partly on a lack of understanding 
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of the exact mechanisms of disease development and progression.16 Additionally, genetic 
predisposition can be viewed in a negative connotation as in the risk of disease 
development while other authors discuss genetic predisposition as being predictive of 
health. 38,40,41 Because of the lack of clear definition, it is difficult to distinguish the 
concept from others in the literature and is considered epistemologically immature. 
Pragmatic 
 The pragmatic principle asks if the concept is useful and applicable in the 
scientific community.24  To address this principle, the concept was analyzed from a 
historical perspective looking longitudinally at the literature.  As the concept of genetic 
predisposition has evolved, the usefulness becomes increasingly apparent.  Earlier work 
on genetic predisposition was reluctant to make definitive claims about the usefulness of 
genetics in predicting outcome.37  As the science of genetics has evolved and a greater 
understanding of the human genome is realized, the usefulness of the concept of genetic 
predisposition has been realized to help stratify risk, predict disease development, and 
determine susceptible patients.15,29,42,43 
 Several studies have examined the utility of genetic predisposition to help predict 
and stratify risk associated with disease development.15,31,34,39,44 Specific diseases include 
colorectal cancer, breast cancer, and diabetes; all of which have been shown to have a 
genetic component.  This is useful to the practitioner to help stratify risk and plan 
treatment along with suggestions for lifestyle modification to decrease risk.36 Also 
emerging in the literature is the idea of genetic predisposition as a screening tool to be 
useful at behavior modification.  In this sense, genetic predisposition can be useful to 
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help predict outcome from treatments or to determine lifestyle modifications to reduce 
disease severity or development. 
Linguistic 
 The linguistic principle asks if the concept is used consistently throughout the 
literature with attention to the meaning of the concept.24  In this regard, genetic 
predisposition has poor linguistic maturity.  It is seen used to describe risk, predict 
outcome, and determine susceptibility.  The context in which the concept is used will 
determine the meaning of genetic predisposition.  For example, if examining the risk of 
developing a disease, genetic predisposition has a negative connotation, as it is though to 
be predictive of disease formation.36  Conversely, genetic predisposition can be seen to 
represent hope when used to show how disease development can be halted or reversed 
with lifestyle and environmental alterations.43,45,46 
 The concept of genetic predisposition has been applied in several contexts across 
varying patient populations and environments.  Although many studies focus on the use 
of genetic predisposition in describing risk, there are other studies and review articles that 
look at genetic predisposition to help stratify risk and determine susceptibility to disease.  
Many terms and meanings can be seen used for the concept of genetic predisposition and 
varying interpretations of these meanings makes the concept of genetic predisposition 
linguistically immature. 
Logical 
 The logical principle aims to determine if the concept of genetic predisposition 
remains clear and holds its boundaries when integrated with other concepts.24  Because 
the epistemological principle lacks clarity, there is an impact on the logical principle.24  
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The analysis of the concept of genetic predisposition revealed that it is not well 
differentiated in the literature so it cannot have clear boundaries compared with other 
concepts.  There are obvious overlaps between risk, prediction, and susceptibility all of 
which make up genetic predisposition as a concept.  This overlap creates ambiguity for 
the concept and blurred boundaries when compared to similar concepts in the literature. 
Limitations 
 Limitations to this concept analysis should be considered.  The exclusion of 
articles not in the English language limited the body of literature reviewed.  Additionally, 
the majority of articles selected were from medicine and genetics literature; there was a 
paucity of literature in nursing, pharmacology, and the social sciences.  Studies were 
selected based on the inclusion criteria set forth above and no formal critique of the 
quality of the studies was performed.  Several of the included studies were review 
articles, some with good methodological quality for searching and performing meta-
analysis.  Other review articles were integrative or narrative reviews and their findings 
lack the weight of higher quality reviews.  There were no identified systematic reviews 
for inclusion. 
Conclusion 
 The principle-based concept analysis of the concept of genetic predisposition has 
revealed an immature, although developing concept.  Genetic predisposition lacks 
epistemological, linguistic, and logical maturity but does have pragmatic maturity and 
usefulness.  Based on this analysis, the concept of genetic predisposition can be defined 
as the use of genetic testing to predict disease, stratify risk, identify susceptibility and 
guide prevention of disease.  Further research into the usefulness of genetic 
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predisposition from the patient perspective would prove invaluable in advancing the 
concept.  Understanding the patient’s perception of genetic predisposition and applying 
this understanding to planning care and screening tools would be beneficial.  
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Chapter 3: Instruments to measure acute pain:  An integrative review 
Riddle, D. (2014). Published in Journal of Pain Management, 6(4).  273-280.21 
Abstract 
 
Context:  Acute pain impacts approximately 45% of the world’s population and is a cause 
of delayed discharge and increased cost to the healthcare system.  If not appropriately 
treated, acute pain can transition into chronic pain resulting in long-term complications. 
 
Objectives:  The objective of this integrative review is to synthesize and describe the 
current instruments used to measure acute pain. 
 
Methods:  A systematic three-stage search strategy was used to review the literature. 
 
Results:  A total of 1754 manuscripts were identified with 8 meeting all inclusion criteria.  
Many of the instruments report various aspects of psychometrics but only 5 report 
reliability, validity, and address feasibility. 
 
Conclusions:  Caution should be exercised when using the currently available instruments 
to measure acute pain.  Since treatment decisions are often based solely on the pain 
measurement instrument, it is important to ensure the chosen instrument is both reliable 
and valid. 
 
Key Words:  acute pain, instrument, review, psychometrics, integrative review 
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Introduction 
 
 Pain, as a concept, is an unpleasant or unwanted feeling often brought on by an 
injury or illness.47  It is estimated that approximately 50% of the American population 
suffers from some form of acute or chronic pain.6  Within the past few years, there has 
been a push internationally to think of pain as the “Fifth Vital Sign” signifying its 
importance to both the patient and healthcare provider.48  Physiological implications of 
pain include:  increased catecholamine release, changes in intrinsic cortisol levels, and 
delayed wound healing as well as psychological problems like depression and anxiety 
49,50.   
Pain is typically considered subjective, can be defined by the person experiencing 
it and can be described in multiple different ways. Theoretically, pain is defined as an 
aversive, uncomfortable, and unwanted sensation.51   To operationally define pain a score 
or rating on a particular measurement scale is often used.  Given the heterogeneity of 
individual pain perceptions, the measurement of pain as a construct has been labeled 
difficult to accurately measure.52   
There are several defined types of pain including acute, chronic, and neuropathic 
pain.  The focus of this review is to critically review the clinically used instruments that 
are aimed or focus on measuring acute pain.  Acute pain is often defined as the normal 
physiologic response to adverse physical stimulus such as trauma, surgery, and acute 
illness.53  The patient’s self-reported pain score often predicates treatment of acute pain 
and there are several instruments in use clinically that purport to measure pain.  The 
purpose of this integrative literature review is to synthesize the best available evidence 
related to quantitative instruments used to measure acute pain. 
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Theoretical Framework 
  Currently, several theories informing the study and pathophysiology of pain.  As 
proposed originally by Melzack and Wall, the gate control theory of pain proposes that 
there is a natural physiologic factor (gate) that modulates pain impulses within the spinal 
cord.54   When a noxious impulse is perceived, large nerve fibers inhibit the transmission 
of some of the stimulus to the brain through afferent nerve tracts.  The gate, or large 
nerve fibers, are effectively closed at this point and stimulation of the dorsal horn neurons 
of the spinal cord does not occur and the perception of pain is decreased.55   
The gating mechanism is influenced by nerve transmission descending from the 
brain and this mechanism is though to explain some aspects of normal physiologic 
functioning in the face of pain.54  Factors influencing the gating mechanism include the 
amount of activity of pain fibers, the presence of analgesic medications, and emotional 
factors such as depression and mood.56  Although the gate control theory of pain does not 
explain everything regarding pain, an in-depth study of this framework does explain why 
various medications and treatment modalities are effective in controlling pain. Within the 
current literature, the gate control theory of pain is one of the accepted frameworks.  
Search Strategy 
 Using a three-step search strategy, the literature was queried to find relevant and 
related studies.  Consultation with a health science reference librarian was utilized to 
hone and refine the search terms and databases.  In the first step of the search, the key 
words “measurement” and “pain” were used in the Cumulative Index to Nursing and 
Allied Health (CINAHL) and MEDLINE databases to ascertain relevant articles and 
additional key words related to the concept of interest. In the next step of the search 
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strategy, all identified key words including acute pain, measurement, instrument, and 
self-report were utilized across CINAHL, MEDLINE, PUBMED, and PsychINFO 
databases.  In the third step of the search, the reference list of all articles meeting 
inclusion criteria was searched for additional manuscripts.  Figure 1 represents the search 
strategy and articles found with each step.  Of note, one article was not found using a 
database search; instead the article was shared by a colleague and is included as it meets 
inclusion criteria.57  Overall, eight articles were utilized in this integrative review and 
Table 1 represents the relevant findings from those articles. 
 For the purposes of this literature review, the focus was on instruments that are 
self-reported measures of acute pain levels.  Instruments that are designed for use in 
sedated or cognitively impaired individuals were excluded.  Additionally, as the focus of 
this review was the adult population, studies related to instruments for use specifically in 
children were also excluded.  Lastly, only instruments that were available in the English 
language were examined.  There are several studies that address the psychometric 
evaluation of instruments for application in other languages; these studies were excluded, 
as no translational services are available.  There was no date-limit set for this literature 
search. 
Results 
 Each of the 8 studies included in this literature review represents a self-reported 
method of measurement of acute pain.  Seven of the eight studies were conducted in the 
United States and one was conducted in England.  Overall, the quality of the studies was 
fair with medium to low-level evidence informing these results.58  The combination of 
these eight studies represents 1,278 total study participants.  Only two of the eight studies 
	  
	   32	  
reported a theoretical framework for their study design.59,60 Three of the eight studies 
reported information on a newly developed scale aimed at measuring acute pain.57,59,61  
The remaining five studies examined psychometric properties of existing instruments 
with new applications or revised designs.  Specific psychometric properties of the eight 
included studies are reported in Table 1.   
Reliability 
 Seven of the eight studies report some measure of reliability.  In pain management 
research, reliability is commonly measured in reliability coefficients, which is a measure 
of stability and consistency over time.62  This is commonly reported as Cronbach’s alpha.  
Six of the eight studies report reliability in terms of internal consistency with Cronbach’s 
alpha scores.  Consistently, the measures of internal consistency as represented by 
Cronbach’s alpha are high (>0.95) across all six studies.  The Visual Analog for Pain 
study used Interclass Correlation Coefficient (ICC) scores between one-minute 
measurements and the McGill Pain Questionnaire study performed three confirmatory 
factor analysis models to test for reliability. 63,64 
Validity 
 Seven of the eight studies report validity results with varying methods for 
calculating and reporting validity.  Two studies reported strong validity but did not 
provide psychometric calculations to support this statement.  The remaining five studies 
reported validity primarily using factors analysis and are reporting convergent validity.  
Where reported, various validity scores are strong but often-exact statistical measures are 
not specifically reported in the manuscript. 
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Discussion 
 This integrative review found eight unique scales that measure acute pain.  
Previous reviews on pain instruments have been broad in scope and have not examined 
pain instruments related specifically to acute pain; therefore, the included eight studies 
represent only those instruments for which studies have examined psychometric 
properties for measurement of acute pain. According to this literature review, the McGill 
Pain Questionnaire and the Visual Analog Scale for Pain are the two most commonly 
used pain instruments in the clinical setting.65   
 Strong reliability scores have been reported in most of the included studies; 
psychometric scoring for validity is sparse.  There are many studies that indicated the 
instrument is valid but did not provide supporting evidence to the reader.  As pain is a 
subjective concept necessitating patient reported scores for quantification, the lack of 
consistent validity scores raises concerns.  As validity of a scale is foundationally a 
measure of how well the instrument measures what it purports to measure, it is possible 
that those instruments with no validity scores are not actually measuring pain but some 
other construct. 
Although reliability was shown to be strong across the entire included 
instruments, the lack of consistent reporting of validity raises concern.  This is especially 
important when considering clinical implications of pain management.  As a subjective 
concept, pain can only be measured indirectly by asking the patient about his or her pain 
levels.  To measure pain, it is necessary to use an instrument to quantify the pain level, 
which is individualized.  Treatment decisions and patient care are planned based on the 
reported pain levels.  If an instrument is used that does not have adequate validity, there 
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is a danger of reporting a score that is not a true representation of the construct being 
measured.  In this situation, potent and lethal medications could be administered and 
inappropriate discharge planning, or incorrect pain management procedures could be 
performed based on an erroneous pain score. 
 Additionally, many studies have shown that pain is far more complex than what is 
represented by a single score.12,50 In measuring pain, this balance between a simple, 
quick, and useful instrument and an instrument that is comprehensive enough to measure 
the multiple facets of pain is difficult.  This balance can be seen in this review by 
examining 1-item instruments, like the PAULA scale, as compared to an instrument like 
the MAPS scale that includes 101-items and requires considerable time to complete.60,66 
The key to finding an appropriate and useful instrument to measure pain is finding an 
instrument that is comprehensive enough to capture all of the facets of pain, short enough 
not to be burdensome to the patient, and has applicability to a wide range of the 
population. 
 One additional consideration that is not addressed in any of the studies is the 
phenomenon of sedation related to pain treatment.  Frequently, acute pain is treated with 
medication that can cause sedation; sometimes this sedation can be profound.  None of 
the studies examined the feasibility of using the instrument with a patient who is being 
actively treated for acute pain episodes.  This raises concerns regarding the reliability of 
the instrument across the spectrum of an episode of acute pain.  A clinical example is the 
patient in the immediate post-operative period receiving opioid analgesics for acute 
surgical pain.  Although important to measure pain in this particular population, 
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reliability of the various available instruments has not been established in the face of a 
sedated patient. 
 Further research aimed at establishing validity of the various instrument used to 
measure acute pain is warranted.  When clinical treatment decisions are based largely on 
scores obtained from pain instruments, it is of paramount importance to ensure the 
instruments are indeed measuring the construct of pain and not some other construct.  
This is critically important given the untoward side effects of the most commonly used 
treatment for acute pain:  opioid analgesics.3  The side effect profile of opioid analgesics 
can range from bothersome pruritus and constipation to severe respiratory depression and 
respiratory arrest.67  Given the significant and dangerous side effects of the treatment of 
acute pain, it is essential that the instruments used to measure the construct on which 
treatment is based be reliable and valid for that construct.  
Conclusion 
 There are several instruments available to measure the construct of pain.  Of the 
eight reviewed instruments, only five have reliability and validity that would warrant 
clinical applicability.  It is useful to have a varying and wide array of instruments that 
will fit with various populations.  It is incumbent on the person administering the 
instrument, however, to make sure that it is reliable, valid, and applicable to the 
population in question.  Fortunately, several instruments with excellent validity and 
reliability are feasible to use in measuring pain. 
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Figure 1.  Search Results 
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Chapter 4:  Clinical utility of pharmacogenomic testing among anesthesia providers:  
A mixed-method study 
Introduction 
Pharmacogenomic testing is becoming more widely used to assist healthcare providers 
make personalize healthcare decisions; however, a stark gap exists in the literature about the 
perceived clinical utility of pharmacogenomic testing in supporting prescriptive decision-making 
among practicing anesthesia providers.  Pharmacogenomic testing can categorize how an 
individual’s variation in deoxyribonucleic acid (DNA) will control drug metabolism by 
programming how the cytochrome P-450 (CYP450) system for drug metabolism functions.5 
With pharmacogenomic testing of an individual’s CYP450 system, the results can support an 
anesthesia provider’s prescriptive decision-making and help minimize ‘guessing’ about which 
drug and dose is best for the patient69.  In the rapidly developing field of personalized medicine, 
in which pharmacogenomics play an integral part, this technology is a key component of helping 
an anesthesia provider determines which medications will work best for their patient. 
Despite the advancement in pharmacogenomic testing technology and the supporting 
interpretative software translating its results, the clinical uptake has been slow.1,5 Although 
clinical outcomes studies demonstrate superior patient outcomes when pharmacologic decisions 
are made based on genetic information, few studies demonstrate the perceived clinical utility of 
pharmacogenomic technology in supporting prescriptive decision-making.6,69,70  Attitudes of 
anesthesia providers towards pharmacogenomic testing and their perceptions of clinical utility of 
the technology in supporting clinical decisions are currently unknown. 
In the United States, there are multiple corporate entities that produce, market, and 
promote pharmacogenomic testing technology and the supporting software for interpretation of 
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the results.  The myriad of differences in the complexity of the testing platforms, the availability 
of the technology in real-world clinical practice settings, and the ability of the patient and the 
anesthesia provider to interpret and apply the results in real-world clinical practice is unknown.  
As the clinical utility of the pharmacogenomic testing among anesthesia providers is 
currently unknown, this study aimed at describing how anesthesia providers in clinical practice 
perceive the usefulness and support the uptake of pharmacogenomic testing as well as quantify 
these perceptions.  Additionally, results of previous work demonstrate that both qualitative and 
quantitative measurement of provider perceptions of clinical utility is necessary before 
advancement of technology into routine clinical practice can be successful.15 Similar work has 
been conducted in the field of hepatology, nutrition, and primary care with feasibility of a mixed-
method approach to establishing clinical utility having been established in these previous 
works.15,16,71 The purpose of this study, then, is to develop a survey based on qualitative 
perceptions of anesthesia providers to better understand the perceived clinical utility of 
pharmacogenomic testing related to clinical prescriptive decision-making. 
Theoretical Framework 
The guiding framework for this study is the Centers for Disease Control and Prevention’s 
(CDC) ACCE Model of Public Health Genomics.22 The model’s dimensions include analytic 
validity; clinical validity; clinical utility; and ethical, legal, and social implications of a genetic 
test.  The clinical utility portion, or outer ring, of the model was used to ground this mixed-
method study (Figure 1).  Anesthesia providers were questioned about knowledge, education, 
perceived barriers, and perceptions of how the technology could impact patient care. 
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Figure 1.  CDC ACCE Model of Public Health Genomics 
Research Design and Methodology 
This study was a sequential qualitative-quantitative mixed-method design that explored 
the perceptions of anesthesia providers regarding the clinical utility of pharmacogenomic testing.  
Participants were any licensed practicing anesthesia provider with unrestricted privileges to 
provide direct patient care.  Ten individuals were recruited to participate in the qualitative phase 
of this study.  Initially, qualitative semi-structured interviews were conducted with 10 practicing 
anesthesia providers.  Following analysis of the qualitative data, probes were developed based on 
the themes that emerged from the qualitative interviews.  These probes were then formulated into 
a quantitative survey designed to quantify the perceptions of anesthesia providers about clinical 
utility of pharmacogenomic testing. 
The qualitative portion of the study utilized case-study methodology as originally 
proposed by Yin.72 Using purposive sampling of 10 practicing anesthesia providers, semi-
structured interviews were conducted.  Questions for the qualitative interview were developed 
using the CDC ACCE Model of Public Health Genomics; Clinical Utility.22 Appendix 1 is the 
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focused interview guide.  Interviews were conducted in the anesthesia provider’s place of 
business, usually in a private office or private consultation room.  The primary investigator 
conducted all interviews, which were audio recorded and transcribed using a professional 
transcription service. 
Following data analysis and thematic development of the qualitative data, probes for a 
quantitative survey were developed from the qualitative data set results.  Survey development 
was based on the Office of Behavioral and Social Sciences and Research guidance on 
development of surveys in the field of human subjects research.73 This survey was initially tested 
with the original 10 participants from the qualitative portion of the study.  This allowed for 
triangulation of the data and revision of the initial survey instrument.73 Cognitive pretesting and 
subsequent item revision were conducted.  The final survey that was administered is attached as 
Appendix 2.  The survey was constructed and administered using the REDCap ™ system.  The 
sample for the quantitative survey was obtained from the American Association of Nurse 
Anesthetists (AANA) and consisted of a random sample of 3000 practicing Certified Registered 
Nurse Anesthetists (CRNA) in the United States and military instillations worldwide.74  The 
survey was distributed electronically, in a blinded fashion, and the respondents could answer on 
a computer, smartphone, or tablet device. 
Data Analysis 
Qualitative data analysis was conducted using case-study methodology as proposed by 
Yin and colleagues.72 Following professional transcription, the individual interview transcripts 
were validated for quality by the primary investigator.  Using multiple-embedded case study 
methodology, each provider was assumed to represent an individual case.  Each anesthesia 
provider represents an individual case because they each care for a cadre of patients; their 
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individual practice represents the sum of the care provided for the cadre of individuals receiving 
an intervention.72,75 Yin indicates that for case-study methodology exploring new concepts, only 
a minimum number of subjects are necessary to achieve data saturation. 
Using NVivo® qualitative data analysis software, data were first deductively coded, 
framed by the CDC ACCE Model of Clinical Utility.22 Using cross-case synthesis methods, each 
anesthesia provider was treated as a separate case and embedded cases were established after the 
first case was coded.  Following deductive coding, inductive coding using constant comparison 
was used to develop key themes in the entire data set.76 The process used to establish rigor of the 
findings was based on a systematic process of coding and interpretation.77 In this process, the 
primary investigator initially reviewed and coded the data based on the ACCE Model.  Next, a 
second, expert qualitative researcher coded the data using the same method.  Systematic 
comparison was made between the primary investigator and the expert methodologist to compare 
findings, negotiate consensus, and ensure rigor of the coding and analysis process.77 
Following qualitative data analysis, the themes that emerged were used to formulate 
survey items aimed at quantifying provider perceptions of clinical utility.  Initially, questions 
were constructed based upon each theme that emerged and those questions underwent cognitive 
pretesting with the group of 10 original participants. Refinement of the questions was then 
conducted. Each question consisted of a unidirectional, Likert-scale type question that aimed to 
measure only one distinct concept.  Two items were constructed per theme for a total of 14-items 
on the final survey. 
Factor analysis using the maximum likelihood extraction was used to analyze the data.78  
This method allows for inferences to be made on the population as a whole based on the 
extracted factors from the sample, which is appropriate for this quantitative data.79,80  Because 
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the factor analysis is exploratory and descriptive, an assumption of the maximum likelihood 
method that each item have a normal distribution was relaxed.  To determine the strength of 
relationship among items as a measure of sampling adequacy the Kaiser-Meyer-Olkin test was 
used to evaluate whether the numbers of significant correlations were sufficient for factor 
analysis.79 Criteria for extraction included visual examination of the Scree plot and as a 
secondary measure, Kaiser’s criteria recommending retention of factors with eigenvalues greater 
than 1.79 To facilitate factor interpretation, factors were rotated using the Direct Oblimin 
technique, which is useful when factors are thought to be related.  Following maximum 
likelihood extraction, Horn’s parallel analysis was carried out to confirm the number of factors 
extracted sufficiently loaded and that minimal residual remained.  Data were analyzed using IBM 
SPSS version 22 for Mac (IBM Corp, Armonk, New York). 
Qualitative Results 
Deductive coding was conducted first.  Framed by the CDC ACCE Model of Public 
Health Genomics, five themes emerged from the analyzed data set.  These themes were: a lack of 
understanding and knowledge about the technology, a lack of facilities to conduct and interpret 
the testing, limited access to the technology, economic concerns about genetic testing, and finally 
legal and ethical implications of ordering genetic testing. 
The first theme that emerged from the data centered on understanding and knowledge 
about pharmacogenomic testing and the interpretation of the results related to clinical decisions.  
Providers indicated they did not have enough education as it relates to pharmacogenomic testing 
to see it as useful in their anesthesia practice: 
“Well, I'm not really sure how it would impact the patients because I don't yet know the 
value of it, I don't know enough about it.” 
 
“We're gaining knowledge that may have utility once we understand it better” 
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Further, providers indicated they lacked facilities to conduct and interpret the findings of 
pharmacogenomic testing.  Most providers indicated that they did not have access to ordering the 
pharmacogenomic test in their facility of practice nor did they know how to order the test if it 
was available.  In answering the question regarding impactfulness of the technology, providers 
indicated they were limited at times in their access to the technology: 
“I guess coming from a rural-type facility and practice, we're limited a lot of times in 
things that are available to us. We may not have a big variety of medications to choose 
from. We tend to be pretty limited to what we have and so, in some ways, it may not 
influence what we do.” 
 
“Currently I'm in a small facility and in a rural facility and it seems like, with medicine, 
that technology is usually centered around the big facilities where they've got the money 
and they've got the ability to study those technologies” 
	  
Anesthesia providers universally were concerned about the economic implications of 
pharmacogenomic testing. Concerns related to the actual cost to the patient, cost to the healthcare 
system as a whole, and costs to the provider if the third-party payers do not cover the testing 
expense were all prominent in the data.  Additionally, providers thought that there is probably 
not a good cost-benefit ratio that is currently available to support the use of pharmacogenomic 
testing in their practice: 
“Did I really need to do an expensive test to figure that out? Or, can I just write a 
prescription and if they responded really well to it, okay, break in half-- take a half one, 
instead. Or, "Wow, that isn't strong enough for you? Okay, well, you have to take two 
instead of one." I didn't need a multi-thousand dollar test to figure that out” 
 
“I think actual barriers may be to some degree the expense of it as it's being developed. I 
think any new technology is usually pretty expensive, until it has been in use for a longer 
period of time. I think that that's the main problem, is going to be money” 
 
“I think instituting the technology is going to be somewhat slow. I think people are really 
resistant to changing things in the first place. It's expensive, I'm sure, to develop this 
technology, and I think that those kinds of things can make an adoption of a technology 
like that somewhat difficult” 
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“If the technology advances, it will have to come to a point where it became affordable 
which takes time and then it may have an impact on rural facilities.” 
 
Anesthesia providers did seem to think that pharmacogenomic testing might be 
advantageous which speaks to the effective benefit of the ACCE Model.  Participants expressed 
the results of pharmacogenomic testing could be useful to plan their anesthetic care.  They 
expressed pharmacogenomic testing would result in less pain, faster recovery times, and provide 
a better, more patient-centered way of delivering anesthesia care.  Providers indicated they think 
the technology would help to focus care, inform decisions, and have positive impacts on patient 
outcomes. 
“I think the advantages to the technology is being able to narrow down with our patients 
what is the best drug to be used for them - the amounts of the drug. So, that we can target 
our patient population to tailor the best anesthetic for them” 
 
“If you could really tailor your anesthetic to that patient then obviously you're going to 
wake up faster, you're going to wake up crisper, you're going to wake up the patient more 
alert, less pain and all the side effects that go along with what we do in the OR so that 
they would have a better experience with that” 
 
 The final theme that emerged from the deductive analysis of the data focused on the 
ethical, legal, and social implications of using pharmacogenomic testing to help inform clinical 
decisions.  Providers generally expressed that there was perhaps an increased liability or 
exposure to risk if they ordered and used a genetic test in practice: 
“I think if I do the test and it shows, on one side, they might be have a very high addictive 
potential and I decide to prescribe anyway, that might increase my liability. Because, I 
knew ahead of time this was going to be a problem. On the other side, if it shows that 
they were a high metabolizer and they would require high doses of opioid, and so, I used 
that to drive my prescribing practices, in that I would write higher doses for them right 
off the bat. And, they either had an adverse event based on the higher dose that I gave 
them, and/or they were diverting and I just thought, Oh well, I misinterpreted that 
information as they are high metabolizers, so, I'm just going to have to keep on giving 
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Following the deductive coding, inductive coding was undertaken using constant 
comparison methods.  The first theme that emerged from the inductive coding was the 
complexity of the technology.  Providers general thought that the pharmacogenomic testing was 
extremely complex and difficult to understand.  They indicated not only was the technology 
complex in interpretation, but understanding when it was indicated an how to go about ordering a 
test, as well as developing their personal comfort in using the test in clinical practice was all very 
confusing: 
“All of the details of that are very confusing to me. It's not something I am comfortable 
with and it's almost to the extent that I perceive the interpretation of the test as something 
that would be so burdensome that I wouldn't want to do it.” 
 
“I think, from my perception, is that we have a test that may or may not be a really 
powerful tool. And, the deal is that they've got a billing code for it, but there is not a lot 
of research out there to show us if you do this test in this scenario it can improve your 
outcomes in this fashion.” 
 
 The final theme was the providers’ feelings that using the pharmacogenomic testing to 
support decision-making would help them avoid complications in the care of their patients.  
Providers felt that they could use the technology to narrow and focus their care and make 
decisions about the very best care possible; not just the status quo.  Additionally, they felt that 
knowledge was power and the more information you know ahead of the proposed anesthetic the 
better the care delivered: 
“My initial inclination would be that if you've got insight into the genetics of a person 
that that would dictate decisions that you make for them, along the lines of malignant 
hyperthermia or something like that. The more you know about the makeup of the person, 
the better able you are to choose appropriate medications.” 
 
“I think the advantages to the technology is being able to narrow down with our patients 
what is the best drug to be used for them - the amounts of the drug. So, that we can target 
our patient population to tailor the best anesthetic for them” 
 
“Less post-operative nausea, and vomiting, etc. Those kinds of things. Less post-
operative pain. I really think that that has a whole lot of promise for patients.” 
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Quantitative Analysis 
Following analysis of the qualitative data, seven themes emerged as concerns anesthesia 
providers had regarding pharmacogenomic testing.  To accomplish factor analysis of the 
proposed instrument, two items were constructed per construct to be measured.  The primary 
investigator developed the 14-item survey and cognitive pre-testing of the survey was 
accomplished with all ten of the qualitative participants.  These qualitative participants practiced 
in community hospitals, rural hospitals, outpatient settings, and academic medical centers.  Their 
years of experience ranged from six to 27 and all were actively practicing anesthesia providers.  
Following refinement of the survey instrument, it was formatted into the REDCap ™ survey 
management system.  Survey items consisted of 14 items on a 0-10 Likert scale with 0 meaning 
completely disagree and 10 meaning completely agree.  All items were written with 
unidirectionality. 
A random sample of 6,000 practicing Certified Registered Nurse Anesthetists in the 
United States and military instillations worldwide were invited to participate in the electronic 
survey.  Through the AANA research division, a random list of potential participants was 
formulated.  This list was generated from the database of CRNAs and filters were applied to only 
sample actively practicing CRNAs.  An invitation letter was electronically distributed to 
participants explaining the purpose of the survey and inviting participation.  An electronic link 
was included in the letter directing potential participants to the electronic survey system.  A total 
of 325 surveys were returned representing a 5% response rate. 
Construct validity was assessed by factor analysis.  A total of 262 complete surveys were 
used in the analysis and cases were excluded list wise if they had any missing variable responses.   
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Results 
Participant characteristics 
The age of the participants was a mean of 48 +/- 11 years.  There were 44% male and 
52% female respondents.  Seventy eight percent of the respondents did not identify a practicing 
specialization while 1% indicated they specialized in neuro anesthesia, 4% in obstetrical 
anesthesia, and 5% in pediatric anesthesia.  Fifty four percent of respondents indicated they 
practiced in a community hospital, 25% in an academic medical center, and 15% in outpatient 
settings.  Seventy two percent of the respondents reported a Master’s degree as their highest 
earned degree with 12% Bachelor’s, 8% Doctorate, and 6% Certificate-prepared.  Participant 
characteristics are presented in Table 1. 
Table 1.  Participant characteristics. 
Age (years) 48 +/- 11 
Gender (% male) 44 
Practice location (%)  
-community hospital 54 
-academic medical center 25 
-outpatient facility 15 
Practice type (%)  











The Kaiser-Meyer-Olkin test (KMO), an overall measure of sampling adequacy, had a 
value of 0.850 which indicated the patterns of correlations were relatively compact and sufficient 
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to reveal distinct and reliable factors.79 Factor analysis resulted in three factors.  Following 
maximum likelihood extraction, Horn’s parallel analysis was carried out to confirm the number 
of factors extracted.  Parallel analysis confirmed that three factors sufficiently loaded and 
minimal residual remained.  Following analyses, the pattern matrix was examined to determine 
the unique contribution of each item to each factor.  Total variance is presented in Table 2 and 
items that loaded on each factor are presented in Table 3. 
Table 2.  Total variance explained 
 
The pattern matrix was examined to examine the unique contributions to each factor.  
Items that loaded on each factor are presented in Table 3. 
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Table 3.  Rotated factor loadings 
Items Factor 1 (benefit) Factor 2 (knowledge) Factor 3 (concerns) 
Tailored care .879   
Quicker wakeup & 
less pain 
.808   
Reduce adverse drug 
events 
.741   
Perceived benefit .467   
Comfort with testing  .803  
Enough knowledge to 
use 
 .753  
Specific training on 
testing 
 .576  
Way to order  .498  
Easy to use  .462  
Location uses testing  .439  
Cost prohibitive   .932 
Cost is reason not 
used 
  .629 
Testing means more 
liability 
  .496 
Ethical concerns 
about testing 
  .400 
Maximum likelihood extraction pattern matrix with Oblimin rotation.  Only related items with 
loadings greater than 0.4 are shown. 
 
Factor 1 was labeled “benefit” because items related to the perceived “benefit” of the 
pharmacogenomic test loaded on this factor.  Factor 2 was labeled “knowledge” because items 
related to understanding the technology and interpretation of the test results loaded on this factor.  
Factor 3 was labeled “concerns” because items related to liability, cost, and ethical 
considerations of pharmacogenomic testing loaded on this factor.  The means for the scores for 
each item that loaded onto each factor are presented in Table 4. 
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Table 4.  Means (standard deviation) of items loaded onto each factor. 
Item Mean (Standard deviation) 
Factor One (Benefit)  
Pharmacogenomic testing would allow me to tailor my anesthetic to 
my patients 
4.6 (3.3) 
If I used pharmacogenomic testing, my patients would wake up 
quicker and in less pain. 
3.4 (2.9) 
By using pharmacogenomic testing, I would reduce adverse drug 
events. 
4.4 (3.3) 
I know how pharmacogenomic testing would benefit my patients. 3.9 (3.0) 
Factor Two (knowledge)  
I am confortable interpreting the results of a pharmacogenomic test 1.2 (2.1) 
I have enough knowledge to use pharmacogenomic testing to help 
me make clinical decisions 
1.2 (2.1) 
I have received some form of training in the use of 
pharmacogenomic testing as it relates to making clinical decisions 
1.6 (2.4) 
In my primary practice location, I have access to or can order 
pharmacogenomic testing 
0.6 (1.4) 
Pharmacogenomic testing easy to use an interpret 2.1 (2.4) 
My primary practice location uses pharmacogenomic testing to help 
providers make clinical decisions 
0.7 (1.5) 
Factor Three (concerns)  
Pharmacogenomic testing is cost prohibitive 4.1 (3.1) 
The reason pharmacogenomic testing is not widely used is cost 4.2 (3.4) 
If I use pharmacogenomic testing in my practice, I am taking on 
additional liability 
2.8 (2.9) 




Discussion and Conclusions 
The use of pharmacogenomic technology to support prescriptive decision-making among 
anesthesia providers has not been established.  Qualitative data shows providers expressed they 
lack the knowledge necessary to use pharmacogenomic testing in clinical practice.  Also, these 
providers expressed that cost and ethical/legal implications of pharmacogenomic testing might 
prohibit them from incorporating this modality in their anesthesia practice.  Anesthesia providers 
expressed that the technology is complex and extremely difficult to understand; further, they 
often do not have access to the technology or the ability to order the test in the place of practice. 
	  
	   56	  
 Anesthesia providers indicated that pharmacogenomic testing is promising and using it 
could result in better, more patient-centered anesthesia care.  This is an interesting finding, as the 
anesthesia provider seems to understand the basic premise behind pharmacogenomics; however, 
they have stated they lack the knowledge necessary to actually use and interpret the findings of a 
pharmacogenomic test.  Providers generally indicated that more personalized prescriptive 
decisions could be made, especially for acute pain and nausea prevention, if pharmacogenomic 
testing is used in anesthesia practice.  Along with providing more personalized care, anesthesia 
providers do indicate that pharmacogenomic testing would help to reduce adverse drug events 
and overall help to reduce poor outcomes in clinical practice. 
 Results of the factor analysis of the quantitative survey show that anesthesia providers’ 
use of pharmacogenomic testing can help to be explained by three phenomena:  lack of 
knowledge, economic and ethical/legal concerns, and perceived or anticipated benefit to the 
patient.  Items from a 14-item survey can be effectively reduced to fewer items that would 
directly question these 3 phenomena. 
 Limitations exist in this study.  First, the qualitative interviews were conducted with 
anesthesia providers that were geographically located in one region of North Texas.  These 
interviews and their resulting data do not represent the anesthesia population as a whole.  
Although saturation was reached in the qualitative analysis, additional interviews could have 
shown additional themes and feelings about pharmacogenomic testing.  Second, a very small 
response rate on the quantitative survey could have biased the results.  The title of the survey 
might have dissuaded individuals from responding, as pharmacogenomics is a foreign concept to 
many practicing anesthesia providers. 
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 Future work should include analysis of the results of each item in the survey along with 
correlational analyses to help determine if there are predictive factors that might play into an 
individual provider’s perceptions and knowledge about pharmacogenomic testing (such as age, 
degree, practice location). 
 Importantly, from this study, it was discovered that anesthesia providers need additional 
education about pharmacogenomic testing.  Providers are unaware of the rather minimal cost of 
the testing and the wide availability of testing through various commercial entities.  Providers are 
also unaware of the specific outcome studies that demonstrate superiority in pain control and 
antiemetic therapy when pharmacogenomic testing is used to guide prescriptive decision-
making.  Additional education in the areas ethical and legal implications of pharmacogenomic 
testing as compared to a wider, more generalized genetic panel is needed.  Interventions aimed at 
helping anesthesia providers understand pharmacogenomic testing, it’s utility, use, and cost is 
necessary. 
Funding: 
This study was supported by an unrestricted grant from the Texas Christian University 
School of Nurse Anesthesia.  Funding for the REDCap ™ system was provided by SCTR – 
Office of Biomedical Services award number NIH/NCATS UL1TR000062. 
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Chapter 5:  Summary and Conclusions 
Synthesis 
 The three manuscripts of this dissertation explore the field of genetics and genetic testing 
as it relates to clinical practice.  The literature has demonstrated that the era of personalized 
medicine is here and healthcare providers need to embrace the field of genetics as part of a 
comprehensive approach to providing healthcare.  Despite the myriad of outcomes studies 
demonstrating how genetics and genetic testing can improve care, it remains a relatively foreign 
idea to most clinicians. 
An analysis of the concept of genetic predisposition (Chapter 2) shows that it remains a 
relatively immature concept.  The concept is seen differently by different groups of people which 
seems to indicate we are all “speaking a different language” when it comes to talking about 
genetics.  Genetics can represent hope and insight to some while is represents risk and threats to 
others.  To healthcare providers, the concept of genetic predisposition overlaps with other 
diagnostic and prognostic testing modalities in stratifying risk, determining treatment, and 
offering statistical insight for patients when speak about disease prognosis.  The concept of 
genetics as predictive is not extremely clear in the literature and this research identifies the need 
to further clarify the concept of genetic predisposition for the patient and the healthcare provider 
alike.   
In relation to this dissertation, the concept analysis of genetic predisposition demonstrates 
that the concept has no meaning to the anesthesia provider.  Chapter 2 demonstrates a complete 
lack of literature in the area of anesthesia providers and understanding of genetic predisposition.  
Chapter 2 helps to define the research question as it relates to understand the concept of 
pharmacogenomic testing (one aspect of genetic predisposition) among anesthesia providers.  
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The concept of genetic predisposition, as it relates to helping predict drug responsiveness, is 
lacking in context, maturity, and formality among anesthesia providers. 
In order to know if a treatment, therapy, or intervention is helpful, it is necessary to have 
psychometrically sound instruments to measure outcomes.  The second manuscript (Chapter 3) is 
an integrative review of the literature about instruments to measure acute pain.  This review 
identifies that pain is very difficult to measure because it is completely subjective.  Furthermore, 
it was demonstrated that pain is multifactorial in nature and there is not one single physiological 
or biomarker that help to identify pain.  This review does demonstrate that there are several 
instruments in current clinical use that have strong psychometric properties to measure acute 
pain.  As anesthesia provider consider the use of pharmacogenomic testing to help make 
decisions regarding pain therapy, the need to psychometrically sound, clinically useful 
instruments to measure outcomes is critical. 
The third manuscript (Chapter 4) of this dissertation explores the perceived clinical utility 
of pharmacogenomic testing to support clinical decision making among anesthesia providers.  
This mixed-method, sequential qualitative quantitative study used case study methodology to 
explore the perceptions of 10 anesthesia providers of pharmacogenomic testing.  Using focused 
semi-structured interviews and multiple embedded case study analysis, it was determined that 
seven themes resonate with anesthesia providers related to pharmacogenomic testing.  Using this 
foundational data, a quantitative survey was constructed to begin to develop a quantitative 
method of measuring perceived clinical utility of pharmacogenomic testing.  This survey was 
electronically distributed and analysis was conducted using factor analysis. 
The third manuscript helps to fill the gap in the literature that exists regarding anesthesia 
provider perceptions of pharmacogenomic testing.  Results of this study shoe that anesthesia 
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providers have a lack of knowledge about how and when to use pharmacogenomic testing.  
Additionally, anesthesia providers have concerns about the ethical and legal implications of 
using genetic testing to help predict drug responses.  Although anesthesia providers were shown 
to perceive benefits in using pharmacogenomic testing, their lack of knowledge about it’s use 
and concerns about ethics and economics severely limits it’s clinical utility. 
The limitations of this dissertation involve the limited and focused population.  As 
preliminary data concerning anesthesia providers only, inferences to other members of the 
healthcare community cannot be made.  Additionally, this data is only preliminary and should be 
considered as pilot data.  Further refinement of the proposed instrument is necessary to more 
precisely measure clinical utility of pharmacogenomic testing among anesthesia providers.  
Future directions include the development of a more robust instrument designed to measure 
clinical utility of pharmacogenomic testing among anesthesia providers.  Also, the development 
of an intervention aimed at increasing anesthesia provider knowledge about pharmacogenomic 
testing is necessary. 
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Appendix 1: Focused Interview Guide: 
 
1. What do you perceive as the advantages to this technology? 
2. What do you perceive as potential or actual barriers to this technology? 
3. How would this technology impact your patients? 
4. How would this technology impact your practice? 
5. In what ways are/would you anticipate using this technology in your practice? 
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